









Markets
/
Stocks
/
nasdaq-bmy
/

Bristol-Myers Squibb Co

BMY

45.620USD

+3.020+7.09%

Close 10/30, 16:00（ET）Quotes delayed by 15 min

92.84BMarket Cap

18.39P/E TTM



Bristol-Myers Squibb Co

45.620

+3.020+7.09%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Bristol-Myers Squibb Co

Currency: USD Updated: 2025-10-30

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bristol-Myers Squibb Co's Score

Industry at a Glance

Industry Ranking

19 / 159

Overall Ranking

52 / 4621

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 29 analysts

Hold

Current Rating

51.633

Target Price

+21.20%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Bristol-Myers Squibb Co Highlights

StrengthsRisks

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Overvalued

The company’s latest PE is 18.32, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.69B shares, decreasing 1.01% quarter-over-quarter.

Held by Irving Kahn

Star Investor Irving Kahn holds 550.68K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-30

The company's current financial score is 9.23, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 12.27B, representing a year-over-year increase of 0.56%, while its net profit experienced a year-over-year increase of 22.02%.

Score

Industry at a Glance

Previous score

9.23

Change



Financials

7.05

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

9.11

Key Metrics

Free cash flow

No Data

Bristol-Myers Squibb Co's Company Valuation

Currency: USD Updated: 2025-10-30

The company’s current valuation score is 8.31, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 18.32, which is 36.97% below the recent high of 25.09 and 193.71% above the recent low of -17.17.

Score

Industry at a Glance

Previous score

8.31

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 19/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-30

The company’s current earnings forecast score is 6.62, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Bristol-Myers Squibb Co is 51.00, with a high of 68.00 and a low of 33.10.

Score

Industry at a Glance

Previous score

6.62

Change

Support & Resistance

No Data

Analyst Rating

Based on 29 analysts

Hold

Current Rating

51.633

Target Price

+21.20%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Bristol-Myers Squibb Co

BMY

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-30

The company’s current price momentum score is 8.74, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 47.02 and the support level at 43.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.26

Change

2.48

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.241

Neutral

RSI(14)

57.866

Neutral

STOCH(KDJ)(9,3,3)

51.327

Buy

ATR(14)

0.901

Low Volatility

CCI(14)

198.810

Buy

Williams %R

6.061

Overbought

TRIX(12,20)

-0.173

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

43.652

Buy

MA10

43.824

Buy

MA20

44.050

Buy

MA50

45.409

Buy

MA100

46.332

Sell

MA200

50.265

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-30

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.81. The latest institutional shareholding proportion is 82.83%, representing a quarter-over-quarter decrease of 0.75%. The largest institutional shareholder is The Vanguard, holding a total of 193.94M shares, representing 9.53% of shares outstanding, with 2.24% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

193.94M

+1.82%

BlackRock Institutional Trust Company, N.A.

99.37M

+1.64%

State Street Investment Management (US)

94.74M

-0.10%

Charles Schwab Investment Management, Inc.

70.80M

+16.82%

JP Morgan Asset Management

67.41M

-3.54%

Capital International Investors

66.16M

-0.46%

Geode Capital Management, L.L.C.

46.18M

+1.59%

Norges Bank Investment Management (NBIM)

33.57M

-4.55%

Columbia Threadneedle Investments (US)

29.38M

+1.21%

Wellington Management Company, LLP

25.82M

+8.83%

Risk Assessment

Currency: USD Updated: 2025-10-30

The company’s current risk assessment score is 8.77, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.33. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.